FLGC vs CRON vs TLRY vs CGC vs ACB

For growth investors, Canopy Growth Corporation (CGC) is the stronger pick with 79.

8% revenue growth year-over-year, versus -75. 6% for Flora Growth Corp. (FLGC). Analysts rate Cronos Group Inc. (CRON) a "Hold" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Cronos Group Inc.

(CRON) delivered a total return of -67. 5%, compared to -99. 8% for Flora Growth Corp. (FLGC). Over 10 years, the gap is even starker: CRON returned +1542% versus FLGC's -99. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Cronos Group Inc.

(CRON) is the lower-risk stock at 0. 93β versus Flora Growth Corp. 's 3. 12β — meaning FLGC is approximately 235% more volatile than CRON relative to the S&P 500. On balance sheet safety, Cronos Group Inc. (CRON) carries a lower debt/equity ratio of 0% versus 76% for Flora Growth Corp. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Canopy Growth Corporation (CGC) is pulling ahead at 79.

8% versus -75. 6% for Flora Growth Corp. (FLGC). On earnings-per-share growth, the picture is similar: Flora Growth Corp. grew EPS 100. 0% year-over-year, compared to -76. 4% for Aurora Cannabis Inc.. Over a 3-year CAGR, CRON leads at 30. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Cronos Group Inc.

(CRON) is the more profitable company, earning -4. 9% net margin versus -266. 3% for Tilray Brands, Inc. — meaning it keeps -4. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CRON leads at -1. 5% versus -277. 9% for TLRY. At the gross margin level — before operating expenses — FLGC leads at 43. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for CGC: 1396.

1% to $14. 47.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Cronos Group Inc.

(CRON) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 93), +1542% 10Y return). Flora Growth Corp. (FLGC) carries a higher beta of 3. 12 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CRON: +1542%, FLGC: -99. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: FLGC is a small-cap quality compounder stock; CRON is a small-cap high-growth stock; TLRY is a small-cap quality compounder stock; CGC is a small-cap high-growth stock; ACB is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.